PCSK9 and coronary artery disorder: A well‐known example is that LOF mutations in PCSK9 reduce serum low‐density lipoprotein (LDL) cholesterol levels and prevent coronary heart disease,21 which greatly contributed to the development of PCSK9 inhibitors, with two approved by the United States Food and Drug Association by 2015.24, 25